Concepedia

Cheryl McAlpine

CM

6

Publications

721

Citations

6

H-Index

2007

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Washington University in St. Louis

The University of Texas MD Anderson Cancer Center

Immunocore (United Kingdom)

The Ohio State University

Cheryl McAlpine is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

2007–2024

6

Publications

6

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock et al. · Clinical Cancer Research · 2020 · 254 citations · Full text

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Sandra P. D’Angelo, Dejka M. Araujo, Albiruni R. Abdul Razak et al. · The Lancet · 2024 · 215 citations · Full text

, , +3

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

David S. Hong, Brian A. Van Tine, Swethajit Biswas et al. · Nature Medicine · 2023 · 171 citations · Full text

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.

Mark R. Middleton, Neil Steven, Thomas Evans et al. · Journal of Clinical Oncology · 2016 · 43 citations

, , +18

Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.

Takami Sato, Paul Nathan, Leonel F. Hernandez‐Aya et al. · Journal of Clinical Oncology · 2017 · 22 citations

, , +15

Rows per page

1–5 of 6